title: Oral and intestinal Candida colonization in patients undergoing hematopoietic stem-cell transplantation.
abstract: We investigated (1) the prevalence and quantity of, as well as risk factors for, orointestinal Candida colonization in patients undergoing hematopoietic stem-cell transplantation (HSCT) and (2) the genetic relatedness of colonizing C. albicans strains. Mouth-wash and stool samples were collected from 77 patients before they underwent HSCT and on days 1, 8, and 15 and were quantitatively cultured. C. albicans isolates were genotyped by microsatellite-marker analysis. The prevalence and quantity of orointestinal Candida colonization varied over time. In 48% (13/27) of multicolonized patients, the same Candida genotype was present in oral and intestinal samples. Oral colonization and decontamination of the gut by vancomycin and paromomycin were risk factors for intestinal Candida colonization.
authors.affiliation: Division of Infectious Diseases, Department of Pulmonology, Medical University of Graz, Graz, Austria.
authors.forename: Ines
authors.initials: I
authors.lastname: Zollner-Schwetz
authors.forename: Holger W
authors.initials: HW
authors.lastname: Auner
authors.forename: Astrid
authors.initials: A
authors.lastname: Paulitsch
authors.forename: Walter
authors.initials: W
authors.lastname: Buzina
authors.forename: Philipp B
authors.initials: PB
authors.lastname: Staber
authors.forename: Petra
authors.initials: P
authors.lastname: Ofner-Kopeinig
authors.forename: Emil C
authors.initials: EC
authors.lastname: Reisinger
authors.forename: Horst
authors.initials: H
authors.lastname: Olschewski
authors.forename: Robert
authors.initials: R
authors.lastname: Krause
mesh_terms: D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000009:adverse effects; D002176:Candida albicans / Q000302:isolation & purification; D002177:Candidiasis / Q000453:epidemiology / Q000209:etiology* / Q000382:microbiology; D002353:Carrier State; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D016867:Immunocompromised Host; D007422:Intestines / Q000382:microbiology*; D008297:Male; D008875:Middle Aged; D009055:Mouth / Q000382:microbiology*; D010303:Paromomycin / Q000009:adverse effects; D015995:Prevalence; D012307:Risk Factors; D014640:Vancomycin / Q000009:adverse effects
chemical_list: D000900:Anti-Bacterial Agents; D010303:Paromomycin; D014640:Vancomycin